Therapeutic update on glycopeptide and lipopeptide antibiotics.
Glycopeptide antibiotics in the form of vancomycin have been available for almost 30 years. In the past, vancomycin usually was reserved as an alternative agent to treat staphylococcal and streptococcal infection in patients with a penicillin allergy or hemodialysis shunt infection. With the increasing frequency of both methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis, now it is often used as a first-line agent. Over a 10-year period, vancomycin sales have increased by almost $1 hundred million. Several new glycopeptide and lipopeptide antibiotics are in various stages of evaluation. While vancomycin resistance to date is a rare phenomenon, these drugs represent a potentially more potent and safer antibiotic alternative to vancomycin. Teicoplanin and daptomycin are two of these investigational agents.
Rotschafer
J C
JC
Section of Clinical Pharmacology, St. Paul-Ramsey Medical Center, MN 55101.
Garrison
M W
MW
Rodvold
K A
KA
D001424:Bacterial Infections / Q000188:drug therapy; D017576:Daptomycin; D004352:Drug Resistance, Microbial; D006020:Glycopeptides / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology; D006801:Humans; D010403:Penicillin Resistance; D010455:Peptides / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology; D011485:Protein Binding / Q000187:drug effects; D013210:Staphylococcus / Q000187:drug effects; D013291:Streptococcus / Q000187:drug effects; D017334:Teicoplanin; D014640:Vancomycin / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*
D006020:Glycopeptides; D010455:Peptides; D017334:Teicoplanin; D014640:Vancomycin; D017576:Daptomycin